BELINDA EDWARDS: Open Payments
NPI 1285815613 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$9,786 in 88 payments from 11 companies in 2025. Trend: 2023 $5,636 · 2024 $11,215 · 2025 $9,786
Speaker / faculty: $7,625Food & beverage: $1,678Travel & lodging: $262Education: $221
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 32 | $8,719 |
| E.R. Squibb & Sons, L.L.C. | 19 | $305 |
| Janssen Pharmaceuticals, Inc | 10 | $220 |
| Neurocrine BioSciences, Inc. | 11 | $214 |
| Alkermes, Inc. | 3 | $65 |
| ABBVIE INC. | 2 | $57 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| Lundbeck LLC | 2 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $38 |
| Axsome Therapeutics, Inc. | 2 | $37 |
Products named: UZEDY, COBENFY, INVEGA SUSTENNA, INGREZZA, AUSTEDO XR, ARISTADA, REXULTI, VRAYLAR.
Industry payments across MS — which companies pay providers there.
